Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Homo sapiens | APEX nuclease (multifunctional DNA repair enzyme) 1 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | proliferative cell nuclear antigen (PCNA), putative | 0.0031 | 1 | 1 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0023 | 0.5617 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0023 | 0.5617 | 0.5 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0.5617 | 0.4297 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0023 | 0.5617 | 0.5617 |
Onchocerca volvulus | Steroid hormone receptor family member cnr14 homolog | 0.0012 | 0 | 0.5 |
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.5617 | 0.5617 |
Giardia lamblia | PcnA | 0.0031 | 1 | 1 |
Leishmania major | proliferative cell nuclear antigen (PCNA), putative | 0.0031 | 1 | 1 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0023 | 0.5617 | 0.5617 |
Loa Loa (eye worm) | proliferating cell nuclear antigen | 0.0031 | 1 | 1 |
Toxoplasma gondii | proliferating cell nuclear antigen PCNA1 | 0.0031 | 1 | 1 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0023 | 0.5617 | 0.5617 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0023 | 0.5617 | 0.5617 |
Toxoplasma gondii | exonuclease III APE | 0.0023 | 0.5617 | 0.4297 |
Echinococcus granulosus | proliferating cell nuclear antigen | 0.0031 | 1 | 1 |
Schistosoma mansoni | proliferating cell nuclear antigen | 0.0031 | 1 | 1 |
Entamoeba histolytica | proliferating cell nuclear antigen, putative | 0.0031 | 1 | 1 |
Plasmodium falciparum | proliferating cell nuclear antigen 1 | 0.0031 | 1 | 1 |
Onchocerca volvulus | Bile acid receptor homolog | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | proliferating cell nuclear antigen, putative | 0.0031 | 1 | 1 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0023 | 0.5617 | 0.5 |
Echinococcus multilocularis | proliferating cell nuclear antigen | 0.0031 | 1 | 1 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0023 | 0.5617 | 0.5 |
Onchocerca volvulus | Protein ultraspiracle homolog | 0.0012 | 0 | 0.5 |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Trichomonas vaginalis | proliferating cell nuclear antigen, putative | 0.0031 | 1 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.5617 | 0.5617 |
Schistosoma mansoni | proliferating cell nuclear antigen | 0.0031 | 1 | 1 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0.5617 | 0.4297 |
Plasmodium vivax | proliferating cell nuclear antigen, putative | 0.0031 | 1 | 1 |
Trypanosoma brucei | proliferative cell nuclear antigen (PCNA), putative | 0.0031 | 1 | 1 |
Trypanosoma cruzi | proliferative cell nuclear antigen (PCNA), putative | 0.0031 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.0045 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 15.8489 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 23.1093 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | = 89.1251 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase). (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.